# US 2022/0007620 A1 · Animal model for amplifying human or animal circulating tumor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0007620 A1
- Document ID: US20220007620A1
- Status: Published application
- Kind: A1
- Application number: 17/289,188
- Filed: 2019-10-29
- Published: 2022-01-13
- Earliest claimed: 2018-10-29
- Assignees: Inovotion; Hospices Civils De Lyon; Universite Claude Bernard Lyon 1
- Applicants: Inovotion; Hospices Civils De Lyon; Universite Claude Bernard Lyon 1
- Inventors: Xavier ROUSSET; Emilien DOSDA; Jean VIALLET; Léa PAYEN-GAY; Denis MAILLET
- Web page: https://patentgrep.com/patent/US20220007620A1

## CPC

- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- C12N 5/0695: {Stem cells; Progenitor cells; Precursor cells}
- C12N 5/0693: {Tumour cells; Cancer cells}
- G01N 33/5011: {for testing antineoplastic activity}
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2227/30: Bird
- A01K 2267/0331: Animal model for proliferative diseases
- A01K 2267/0393: Animal model comprising a reporter system for screening tests
- C12N 2503/02: Drug screening
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to an avian model enabling the amplification of human or animal circulating tumour cells (CTC) and to the use thereof for monitoring and determining the sensitivity of a patient or an animal suffering from cancer to one or more therapeutic agent(s), as well as for screening novel therapeutic agents intended for the treatment of cancer.

## Claims

### Claim 1

Embryonated bird's egg model comprising human or animal circulating tumour cells (CTC) isolated from a sample of a patient or an animal suffering from cancer, said CTC being grafted at the level of the chorioallantoic membrane (CAM) of an embryonated egg being at a development stage which corresponds to the formation of the CAM and equivalent to at least 8 days of development in chickens at the moment of the graft.

### Claim 2 (depends on 1)

Model according to claim 1, characterised in that the embryonated egg is at a development stage of at the most 20 days.

### Claim 3 (depends on 1, 2)

Method for preparing an embryonated bird's egg model according to any one of claim 1 or 2 enabling the amplification of human or animal circulating tumour cells (CTC) isolated from a sample of a patient or an animal suffering from cancer, said method comprising the following steps:
grafting CTC isolated from said sample at the level of the chorioallantoic membrane (CAM) of an embryonated bird's egg which is at a development stage corresponding to the formation of the CAM and equivalent to at least 8 days of development in chickens,
optionally incubation of the embryonated egg thereby grafted for at least 12 hours.

### Claim 4 (depends on 3)

Method for amplifying human or animal circulating tumour cells (CTC) isolated from a sample of a patient or an animal suffering from cancer, comprising the following steps:
a) preparation of an embryonated egg model using the method according to claim 3,
b) collection of tumours that develop from CTC that are amplified,
c) optionally, recovery of CTC from the tumours collected at step b).

### Claim 5 (depends on 3, 4)

Method for amplifying human or animal circulating tumour cells (CTC) according to claim 4, characterised in that it comprises the following steps:
a) preparation of a first embryonated egg model using the method according to claim 3,
b) collection of tumours that develop from CTC that are amplified,
b1) grafting the tumours collected at step b) at the level of the chorioallantoic membrane (CAM) of a second embryonated bird's egg incubated beforehand up to a development stage corresponding to the formation of the CAM and equivalent to at least 8 days of development in chickens,
b2) optionally, incubation of this second embryonated egg thereby grafted for at least 12 hours,
b3) collection of tumours that develop from the tumours grafted at step b1), and optionally,
c) recovery of CTC from the tumours collected at step b3).

### Claim 6 (depends on 4, 5)

Method for determining the sensitivity of a patient or an animal suffering from cancer to one or more therapeutic agent(s), characterised in that it comprises:
amplification of circulating tumour cells (CTC) isolated from a sample of said patient or animal suffering from cancer according to the method such as defined in any one of claims 4 to 5,
grafting the tumours thereby collected at the level of the chorioallantoic membrane (CAM) of a new embryonated bird's egg incubated beforehand up to a development stage corresponding to the formation of the CAM and equivalent to at least 8 days of development in chickens,
administration of the therapeutic agent(s) in the embryonated egg at least 12 hours after the graft,
study of the effect of the therapeutic agent(s) thereby administered on tumorigenesis of the collected tumours that have developed in this new grafted embryonated egg.

### Claim 7 (depends on 6)

Method for determining the sensitivity of a patient or an animal suffering from cancer to one or more therapeutic agent(s) according to claim 6, characterised in that the study of tumorigenesis comprises the assessment or the measurement of different parameters such as tumour growth, metastatic invasion, angiogenesis, neo-angiogenesis, inflammation and/or tumour immune infiltration, toxicity on the tumour and/or on the embryo as a whole.

### Claim 8 (depends on 3)

Method for monitoring a patient or an animal suffering from cancer, comprising:
preparation of a first embryonated bird's egg according to claim 3 with CTC isolated from a sample of said patient or animal at a time T1, and tumorigenesis study of the tumours that develop in this first embryonated egg,
preparation of a second embryonated bird's egg according to claim 3 with CTC isolated from a sample of the same patient or animal at a time T2, and tumorigenesis study of the tumours that develop in this second embryonated egg,
comparison of the tumorigenesis of tumours that have developed in the first and in the second embryonated eggs.

### Claim 9 (depends on 3)

Method for screening therapeutic agents intended for the in vivo treatment of cancer, comprising:
preparation of an embryonated egg model using the method according to claim 3,
administration of one or more candidate agents in the embryonated egg at least 12 hours after the graft,
study of the effect of the therapeutic agent(s) thereby administered on the tumorigenesis of tumours that have developed in the grafted embryonated egg.
